Bosnia and Herzegovina (BiH) is a country with an estimated population of 3.825,000 people4, located in the western part of the Balkan Peninsula.
The estimated number of people who inject drugs (PWID) in BiH is 9,500. Stigma and discrimination towards PWID and other KAPs is still present in BiH and shapes public and stakeholder opinion.
With a HIV prevalence of less than 0.1% in the general population and less than 5% among identified KAPs (PWID, MSM and W), BiH falls among the low prevalence countries. Hepatitis C prevalence among PWID - 50%. HCV treatment is financed by the health insurance fund of each entity since 2005.
Since 2006, BiH has been a recipient of Global Fund to Fight AIDS, Tuberculosis, and Malaria grants to support the country’s HIV and TB programs. However, as BiH has been classified as an upper-middle income country by the World Bank and as a low HIV prevalence country, it will not be supported by Global Fund resources after September 2016. Nowadays, BiH is going through a transition process guided by a transition plan to transfer ownership of the HIV program from the Global Fund to domestic structures.